RxDoctor Payments Data

Ilene Weizer, MD

Obstetrics & Gynecology · Pottsville, PANPI 1093713166

Payments from drug & device makers

$4,089in general payments, 2019–2025

Across 177 payments — averaging $23.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • AbbVie$694
  • Astellas Pharma US Inc$325
  • Sumitomo Pharma America, Inc.$200
  • Pfizer$169
  • Exeltis, USA Inc.$148
  • plus $1K from 25 others

What the payments were for

  • Travel & lodging$99024%
  • Food & beverage$2,81369%
  • Education$2877%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,089 in reported general payments places this provider in the 90th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.

See all obstetrics & gynecology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$79,244
Medicare patients
306
Services billed
1,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron38$37,339
PremarinEstrogens, Conjugated36$14,364
GemtesaVibegron15$13,891
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl96$11,170
Estradiol100$8,245
Clobetasol Propionate44$1,875
Raloxifene Hcl19$1,159
ValacyclovirValacyclovir Hcl25$1,110
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip56$1,047
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc24$922
Medroxyprogesterone Acetate25$765
Buprenorphine Hcl12$464
Oxybutynin Chloride ErOxybutynin Chloride22$453
Ibandronate Sodium12$423
VienvaLevonorgestrel/Ethin.Estradiol25$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$325$37,33938 claims
PfizerPremarin$169$14,36436 claims
Sumitomo Pharma America, Inc.Gemtesa$200$13,89115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.

Other obstetrics & gynecology in Pottsville

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →